Paper Details

  1. Home
  2. Paper Details

Optimal HIV Postexposure Prophylaxis Regimen Completion With Single Tablet Daily Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine Compared With More Frequent Dosing Regimens.

Author: GelmanMarcy, GrassoChris, JainSachin, JonesDaniel, MayerKenneth H, MimiagaMatthew J, OldenburgCatherine, ZaslowShayne

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

Elvitegravir/cobicistat/TDF/FTC was safe and well tolerated for PEP, with higher regimen completion rates than more frequently dosed PEP regimens.
Paper Details　
Original Abstract of the Article :
STRUCTURE: The study evaluated elvitegravir/cobicistat/tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) ("Quad pill") for postexposure prophylaxis (PEP). BACKGROUND: HIV-exposed individuals may benefit from PEP, but completion rates have been suboptimal because of regimen complexity and side...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/28696345

データ提供：米国国立医学図書館（NLM）

Optimal HIV Postexposure Prophylaxis (PEP) Regimen Completion: A Study of Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine

This research examines the crucial issue of postexposure prophylaxis (PEP) for HIV, exploring the effectiveness of a single-tablet daily regimen compared to more frequently dosed regimens. It's like a camel trekking through a desert of complex treatment options, seeking to find the most effective and convenient path to prevent HIV infection.

Finding the Right Path in the Desert of PEP: A Single-Tablet Regimen Shows Promise

The study reveals that the single-tablet daily regimen of elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine (Quad pill) demonstrates significantly higher completion rates compared to more frequently dosed PEP regimens. This finding suggests that a simplified and convenient regimen can significantly improve adherence and potentially reduce the risk of HIV infection. It’s like finding a shortcut through the desert, making the journey to prevent HIV infection easier and more efficient.

Improving Adherence: A Key Oasis in HIV Prevention

This research highlights the importance of patient adherence in HIV prevention. By developing simplified and convenient treatment regimens, we can improve adherence and ultimately reduce the risk of HIV infection. It's like discovering a refreshing oasis in the desert of HIV prevention, a place where patients can find the support and resources they need to successfully manage their treatment and protect themselves from this serious disease.

Dr. Camel's Conclusion

This study offers a promising new approach to HIV PEP, demonstrating that a single-tablet daily regimen can significantly improve adherence and potentially reduce the risk of HIV infection. By finding innovative ways to simplify and streamline treatment, we can make a real difference in the fight against HIV.
Date :
  1. Date Completed 2017-08-07
  2. Date Revised 2020-09-30
Further Info :

Pubmed ID

28696345

DOI: Digital Object Identifier

NIHMS872895

Related Literature

Article Analysis
・Side Effects of emtricitabine and tenofovir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.